Leerink Partnrs Increases Earnings Estimates for NeuroPace

NeuroPace, Inc. (NASDAQ:NPCE) – Stock analysts at Leerink Partnrs boosted their FY2025 earnings estimates for NeuroPace in a research note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst M. Kratky now expects that the company will earn ($0.77) per share for the year, up from their prior estimate of ($0.80). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2025 earnings at ($0.19) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.39 EPS.

Other equities research analysts have also issued research reports about the company. Leerink Partners reissued an “outperform” rating and set a $19.00 price objective on shares of NeuroPace in a research note on Wednesday. Wells Fargo & Company raised their price target on NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a research report on Wednesday. Zacks Research cut shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $17.33.

NeuroPace Stock Down 1.5%

NPCE opened at $12.78 on Friday. The firm has a market capitalization of $425.70 million, a P/E ratio of -16.82 and a beta of 1.90. NeuroPace has a one year low of $6.63 and a one year high of $18.98. The company has a fifty day moving average price of $10.29 and a 200-day moving average price of $10.86. The company has a debt-to-equity ratio of 3.17, a current ratio of 4.86 and a quick ratio of 4.51.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 136.60%. The business had revenue of $27.35 million for the quarter, compared to analyst estimates of $24.64 million. NeuroPace has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On NeuroPace

Several institutional investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC grew its position in NeuroPace by 194.2% during the 3rd quarter. Essex Investment Management Co. LLC now owns 216,722 shares of the company’s stock worth $2,234,000 after acquiring an additional 143,063 shares during the last quarter. Western Wealth Management LLC purchased a new stake in shares of NeuroPace during the third quarter valued at approximately $237,000. Principal Financial Group Inc. boosted its stake in shares of NeuroPace by 118.7% during the third quarter. Principal Financial Group Inc. now owns 39,504 shares of the company’s stock valued at $407,000 after purchasing an additional 21,439 shares during the period. AlphaQuest LLC grew its holdings in shares of NeuroPace by 131.5% in the third quarter. AlphaQuest LLC now owns 17,087 shares of the company’s stock worth $176,000 after purchasing an additional 9,707 shares during the last quarter. Finally, Lazard Asset Management LLC increased its stake in shares of NeuroPace by 2,445.5% in the second quarter. Lazard Asset Management LLC now owns 78,885 shares of the company’s stock worth $878,000 after buying an additional 75,786 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.